Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Open access
Awad, Mark M., Govindan, Ramaswamy, Balogh, Kristen N., Spigel, David R., Garon, Edward B., Bushway, Meghan E., Poran, Asaf, Sheen, Joong Hyuk, Kohler, Victoria, Esaulova, Ekaterina, Srouji, John, Ramesh, Suchitra, Vyasamneni, Rohit, Karki, Binisha, Sciuto, Tracey E., Sethi, Himanshu, Dong, Jesse Z., Moles, Melissa A., Manson, Kelledy, Rooney, Michael S., Khondker, Zakaria S., DeMario, Mark, Gaynor, Richard B., Srinivasan, Lakshmi · 2022 · Cancer Cell

Abstract

Neoantigens arising from mutations in tumor DNA provide targets for immune-based therapy. Here, we report the clinical and immune data from a Phase Ib clinical trial of a personalized neoantigen-vaccine NEO-PV-01 in combination with pemetrexed, carboplatin, and pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). This analysis of 38 patients treated with the regimen demonstrated no treatment-related serious adverse events. Multiple parameters including baseline tumor immune infiltration and on-treatment circulating tumor DNA levels were highly correlated with clinical response. De novo neoantigen-specific CD4+ and CD8+ T cell responses were observed post-vaccination. Epitope spread to non-vaccinating neoantigens, including responses to KRAS G12C and G12V mutations, were detected post-vaccination. Neoantigen-specific CD4+ T cells generated post-vaccination revealed effector and cytotoxic phenotypes with increased CD4+ T cell infiltration in the post-vaccine tumor biopsy. Collectively, these data support the safety and immunogenicity of this regimen in advanced non-squamous NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2022.08.003

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 234

Metadata

Authors
Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V., Esaulova, E., Srouji, J., Ramesh, S., Vyasamneni, R., Karki, B., Sciuto, T. E., Sethi, H., Dong, J. Z., Moles, M. A., Manson, K., Rooney, M. S., Khondker, Z. S., DeMario, M., Gaynor, R. B., & Srinivasan, L.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2022-09
Volume
40
Issue
9
Pages
1010-1026.e11
ISSN
1535-6108 (ISSN-L)
OpenAlex
W4293043553
Cited by
234
References
22
FWCI
16.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.